Abstract:HIV envelope transmembrane glycoproteins gp41 (HIV-1) and gp36 (HIV-2) present high variability and play a key role in the HIV-host cell membrane's fusion, as a target for human broadly neutralizing antibodies (bnAbs) and drugs. Thus, a better knowledge of amino acid (aa) conservation across structural domains and HIV variants can help to identify conserved targets to direct new therapeutic and diagnostic strategies. All available gp41/gp36 nucleotide sequences were downloaded from Los Alamos National Laboratory (LANL) HIV Sequence Database, selecting 17,078 sequences ascribed to HIV-1 and HIV-2 variants with ≥3 sequences. After aligning and translating into aa with MEGAv6.0, an in-house bioinformatics program (EpiMolBio) was used to identify the most conserved aa and the aa changes that were specific for each variant (V-markers) vs. HXB2/BEN (HIV-1/HIV-2) reference sequence. We analyzed the presence of specific aa changes among V-markers affecting infectivity, gp41 structure, function, or resistance to the enfuvirtide viral fusion inhibitor (T-20). We also inferred the consensus sequences per HIV variant, describing in each HIV-1 group (M, N, O, P) the conservation level along the complete gp41 per structural domain and locating in each binding site the anti-gp41 human Abs (bnAbs and non bnAbs) described in LANL. We found 38.3/59.7% highly conserved aa present in ≥90% of the 16,803/275 gp41/gp36 sequences ascribed to 105/3 HIV-1/HIV-2 variants, with 9/12.6% of them showing complete conservation across LANL sequences. The fusion peptide, its proximal region, the N-heptad repeat, and the membrane-proximal external region were the gp41 domains with ≥84% of conserved aa in the HIV-1 consensus sequence, the target of most Abs. No natural major resistance mutations to T-20 were observed. Our results show, for the first time, a complete conservation study of gp41/gp36 per variant in the largest panel of HIV variants analyzed to date, providing useful information for a more rational design of drugs, vaccines, and molecular detection tests targeting the HIV transmembrane glycoprotein.

HIV-2 Transmembrane Protein gp36 Binds to the Putative Cellular Receptor Proteins P45 and P62

The C Domain of HIV-1 Gp41 Binds the Putative Cellular Receptor Protein P62.

Biological Function Of Hiv-1 Transmembrane Protein Gp41 - A Study On A Putative Cellular Receptor Of Gp41

Characterization of Interaction Between C-domain on HIV-1 Gp41 and the Putative Receptor Protein P62.

HIV-1 Gp41 by N-domain Binds the Potential Receptor Protein P45.

Biological Function of H1V-1 Transmembrane Protein Gp41

The Human Monocyte Cell Line U937 Binds HIV-1 Gp41 by Proteins of 37, 45, 49, 62 and 92 Kda.

HIV-1 gp41 shares a common immunologic determinant with human T, B and monocyte cell lines

HIV-1 Gp41 Binds to Several Proteins on the Human B-cell Line, Raji.

Affinity Capillary Electrophoresis: Study of the Binding of HIV-1 Gp 41 with a Membrane Protein (P45) on the Human B Cell Line, Raji

Antibodies against human IFN-alpha and -beta recognized the immunosuppressive domain of HIV-1 gp41 and inhibit gp41-binding to the putative cellular receptor protein p45.

HIV-1 gp41 selectively inhibits spontaneous cell proliferation of human cell lines and mitogen- and recall antigen-induced lymphocyte proliferation

HIV Transmembrane Glycoprotein Conserved Domains and Genetic Markers Across HIV-1 and HIV-2 Variants

A Common Immunological Epitope Existing between HIV-1 gp41 and Human Interferon-α and -β

Human interferon-β inhibits binding of HIV-1 gp41 to lymphocyte and monocyte cells and binds the potential receptor protein P50 for HIV-1 gp41

Antibodies against human IFN-α and -β recognized the immunosuppressive domain of HIV-1 gp41 and inhibit gp41-binding to the putative cellular receptor protein p45

Identification of Critical Antibody-Binding Sites in the HIV-1 Gp41 Six-Helix Bundle Core As Potential Targets for HIV-1 Fusion Inhibitors

Identification of human immunodeficiency virus type 1 (HIV-1) gp120-binding sites on scavenger receptor cysteine rich 1 (SRCR1) domain of gp340

Affinity maturation and characterization of a human monoclonal antibody against HIV-1 gp41.

Study of the interaction of HIV-1 and HIV-2 envelope glycoproteins with the CD4 receptor and role of N-glycans.

HIV-1 Gp41 by a Common Immunological Epitope Induces Increased Levels of Antibodies Against Human Interferon-Β in HIV-1 Positive Individuals